DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Kilitch Drugs (India) Bull Case vs Bear Case for 2026

Univest 3 hrs ago·15 Sept 2026, 9:25 pm

Kilitch Drugs (India) is a key player in the Indian consumer healthcare market, focusing on the distribution and marketing of pharmaceutical products. The company's future performance will depend on its ability to execute its growth strategy, particularly in expanding its product portfolio and distribution network. Investors are closely watching the company's progress in this area, as it is a critical factor in determining its long-term success.

The bull case for 2026 centers on the company's potential to capture a larger market share in India's growing pharmaceutical sector. This could be driven by successful product launches, strategic partnerships, and efficient cost management. Conversely, the bear case highlights risks such as increased competition, regulatory challenges, and the need for sustained investment in marketing and research.

For investors, the key is to monitor the company's quarterly results, particularly its revenue growth and margin expansion. Additionally, keeping an eye on industry trends and regulatory changes will provide valuable insights into the company's future trajectory. The coming quarters will be crucial in validating the assumptions behind both the bull and bear cases.